Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid biopsies should become standard in oncology.

Newland explains how current US FDA-approved tests can detect some types of advanced cancers, predict prognosis, and help healthcare providers make treatment decisions. And importantly, Newland describes how live cell liquid biopsies are a UK-developed technology that aligns with national efforts to modernise cancer diagnostics, as well as potentially reduce healthcare costs by minimising ineffective treatments.

You can listen to episode 238 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.